E
ENSC
Ensysce Biosciences Inc
0.4050
-0.0095-2.29%Opening10:38 09/24 EDT
OPEN/PREV CLOSE0.4173/0.4190
TODAY RANGE0.4118-0.4398
VOL544.91K
MARKET CAP8.36M
52 WEEK RANGE0.2300-2.750
AVG VOL (3M)13.99M
% TURNOVER2.76%
TURNOVER--
P/E (TTM)-0.1562
% RANGE6.68%
EPS(TTM)-2.7523
P/E(FORWARD)-0.3943
P/B-8.9170
BVPS-0.0482
DIVIDEND--
P/S0.3881
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP7.93M
SHARES OUTSTANDING19.46M
NEXT EARNINGS11/12-11/16
FREE FLOAT18.45M
LOT SIZE1
EX-DATE12/06/2024
News
Press Releases
Financial Reports
Profile
TipRanks·09/29 13:01
Ensysce Biosciences Updates Series C Preferred Stock Terms
TipRanks·09/24 12:40
Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA
TipRanks·09/15 13:25
Ensysce Biosciences advances CRPS program at Painweek 2026
TipRanks·09/14 12:20
Ensysce professor to speak at FDA public hearing on psychedelic drugs
TipRanks·08/31 12:40
Ensysce completes enrollment for final phase of PF614-MPAR-102 study
TipRanks·08/25 22:01
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
TipRanks·08/24 21:28
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
TipRanks·08/19 02:11
Major Insider Move Sparks Fresh Buzz Around Ensysce Biosciences Stock
Benzinga·08/13 17:05
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga·08/06 17:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga·08/06 13:43
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
TipRanks·08/06 12:55
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio
Same Industry
Name/Symbol
Change%
Price